Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 6/20 | 0.68 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CCR3 | P51677 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7665338 | 0.81 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL7559649 | 0.81 | P2RX7 (0.81) | P2RX7 | |
| SCHEMBL3951445 | 0.76 | P2RX7 (0.64) | P2RX7CHRM3GAA | |
| SCHEMBL5142841 | 0.75 | NPC1 (0.44) | P2RX7LMNATP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL5334659 | 0.74 | CYP4F2 (0.46) | P2RX7LMNATP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL7661977 | 0.73 | P2RX7 (0.61) | P2RX7CHRM3GAA | |
| SCHEMBL8081000 | 0.73 | CA1 (0.55) | P2RX7LMNATP53ALDH1A1CA1 | |
| SCHEMBL7665305 | 0.72 | P2RX7 (0.83) | P2RX7 | |
| SCHEMBL7658512 | 0.72 | P2RX7 (0.54) | P2RX7LMNATP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL6485285 | 0.71 | P2RX7 (0.53) | P2RX7LMNATP53SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207577-A1 | Mixture of a P2X7 (purinergic) receptor antagonist, and a corticosteroid; 1-adamantylalkylamide derivatives with benzyl or pyridyl group; respiratory system disorders, chronic obstructive pulmonary disease; antiasthmatics; formoterol, budesonide; kits | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | claimed |
| US-20070281931-A1 | Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | US | claimed |
| US-20070082930-A1 | Pharmaceutical composition comprising a p2x7 receptor antagonist and a nonsteroidal anti-inflammatory drug | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | US | claimed |
| JP-2007505900-A | — | — | 2007-03-15 | — | — | JP | claimed |
| US-20070032465-A1 | Pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor alpha | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | claimed |
| WO-2007008157-A1 | NEW COMBINATION 2 | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | claimed |
| US-20070010497-A1 | Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | claimed |
| US-20060247257-A1 | Combination | ASTRAZENECA AB (SE) | 2006-11-02 | — | — | US | claimed |
| EP-1663224-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7 RECEPTOR ANTAGONIST AND A NONSTEROIDAL ANTI INFLAMMATORY DRUG | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | claimed |
| EP-1644042-A1 | A PHARMACEUTICAL COMPOSITION CONTAINING A P2X7 RECEPTOR ANTAGONIST AND METHOTREXATE | AstraZeneca AB (SE) | 2006-04-12 | — | — | EP | claimed |
| EP-1644041-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7 ANTAGONIST AND SULFASALAZINE | AstraZeneca AB (SE) | 2006-04-12 | — | — | EP | claimed |
| WO-2005025571-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7 RECEPTOR ANTAGONIST AND A NONSTEROIDAL ANTI INFLAMMATORY DRUG. | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | claimed |
| WO-2004105797-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7 ANTAGONIST AND SULFASALAZINE | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | claimed |
| WO-2004105796-A1 | A PHARMACEUTICAL COMPOSITION CONTAINING A P2X7 RECEPTOR ANTAGONIST AND METHOTREXATE | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | claimed |
| EP-3402469-B1 | P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) | INST NAT SANTE RECH MED (FR) | 2021-01-06 | — | — | EP | disclosed |
| US-10548980-B2 | P2X7 receptor antagonists for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV) | INSERM (Institut National de la Santé et de la Recherche Médicale (FR) | 2020-02-04 | — | — | US | disclosed |
| US-20190022223-A1 | P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) | INSERM (INSTITUT NATIONAL DE LA SANTÉ ET LA SANTÉ ET DE LA RECHERCHE MÉDICALE) (FR) | 2019-01-24 | — | — | US | disclosed |
| WO-2004105796-A1 | A PHARMACEUTICAL COMPOSITION CONTAINING A P2X7 RECEPTOR ANTAGONIST AND METHOTREXATE | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004105798-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7-RECEPTOR ANTAGONIST AND A TUMOUR NECROSIS FACTOR α | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004073704-A1 | NEW COMBINATION | ASTRAZENECA AB (SE) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281931-A1 | Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate | P2RX7, P2RY1, P2RX5 | P2RX7 1/4885CHRM3 875/4885LMNA 2260/4885 |
| US-10548980-B2 | P2X7 receptor antagonists for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV) | P2RX7, P2RX1, P2RX5 | P2RX7 1/4885CHRM3 552/4885LMNA 2362/4885 |
| US-20070010497-A1 | Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine | P2RX7, P2RX5, P2RX2 | P2RX7 1/4885CHRM3 1480/4885LMNA 3348/4885 |
| US-20070082930-A1 | Pharmaceutical composition comprising a p2x7 receptor antagonist and a nonsteroidal anti-inflammatory drug | P2RX7, P2RX3, P2RX5 | P2RX7 1/4885CHRM3 752/4885LMNA 1586/4885 |
| US-20060247257-A1 | Combination | P2RX7, PCSK9, P2RX1 | P2RX7 1/4885CHRM3 3011/4885LMNA 226/4885 |
| US-20080207577-A1 | Mixture of a P2X7 (purinergic) receptor antagonist, and a corticosteroid; 1-adamantylalkylamide derivatives with benzyl or pyridyl group; respiratory system disorders, chronic obstructive pulmonary disease; antiasthmatics; formoterol, budesonide; kits | P2RY1, P2RX3, P2RX7 | P2RX7 3/4885CHRM3 22/4885LMNA 2212/4885 |
| US-20190022223-A1 | P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) | P2RX7, P2RX1, P2RX5 | P2RX7 1/4885CHRM3 552/4885LMNA 2362/4885 |
| US-20070032465-A1 | Pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor alpha | P2RX7, P2RX1, P2RX5 | P2RX7 1/4885CHRM3 1219/4885LMNA 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.